Electrocardiogram Abnormalities with Atazanavir and Lopinavir/Ritonavir

REFERENCES

• Struble K, Murray J, Cheng B, et al. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS. 2005;19:747–756.
   PubMed Web of Science ®Google Scholar
• Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. June 17,1998. Available at: http://aidsinfo.nih.gov. Accessed September 5,2008.
   Google Scholar
• Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis. 2005;18:1–7.
   PubMed Web of Science ®Google Scholar
• Basso S, Solas C, Quinson AM, et al. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. J Acquir Immune Defic Syndr 200231: 115–117.
   Google Scholar
• Kashuba AD, Tierney C, Downey GF, et al. Combining fos-amprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005;19:145–152.
   PubMed Web of Science ®Google Scholar
• Khanlou H, Graham E, Farthing C. Drug interactions between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS. 2002;16:797–798.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Leith J, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in com-bination with saquinavir (SQV), amprenavir (APV), or lopi-navir (LPV): Interim analysis of B11182.51. In: Program and abstracts from the XV IAS Conference; July 11–16, 2004; Bangkok, Thailand. Abstract WeOrB1236.
   Google Scholar
• Rosenbach KA, Allison R, Nadler JP. Daily dos-ing of highly active antiretroviral therapy. Clin Infect Dis. 2002;34:686–692.
   PubMed Web of Science ®Google Scholar
• Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care. 2004;3:92–98.
   Google Scholar
• Haas DW, Zala C, Schrader S, et al. Therapy with atazana-vir plus saquinavir in patients failing highly active antiretro-viral therapy: a randomized comparative pilot trial. AIDS. 2003;17:1339–1349.
   PubMed Web of Science ®Google Scholar
• Zilly M, Winzer R, Nolte C, et al. Double PI boosting with atazanavir and fos-amprenavir: favourable pharmacoki-netics. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28–30, 2005; Quebec City, Quebec, Canada. Abstract 93.
   Google Scholar
• Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic inter-action study of total, unbound plasma and cellular expo-sures. Antivir Ther. 2006;11:53–62.
   PubMed Web of Science ®Google Scholar
• Vezina HE, Tschampa JM, Jennings C, et al. Steady-state pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) co-administered with atazanavir in HIV infected subjects. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20–22, 2006; Lisbon, Portugal. Abstract 48.
   Google Scholar
• Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopi-navir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS. 2006;20:1131–1139.
   PubMed Web of Science ®Google Scholar
• Pham PA, Flexner CW, Parsons T, et al. Beneficial phar-macokinetic interaction between atazanavir and lopinavir/ ritonavir. J Acquir Immune Defic Syndr. 2007;45:201–205.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Risk Assess-ment Tool. Available at: http://hp2010.nhIbihin.net/atpiii/calculatorasp?usertype=prof#moreinfo. Accessed July 10,2009.
   Google Scholar
• Product Information. Reyataz (atazanavir sulfate) capsules. Princeton, NJ: Bristol-Myers Squibb; March 2008.
   Google Scholar
• Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-näive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265–272.
   PubMed Web of Science ®Google Scholar
• Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7:317–322.
   PubMed Web of Science ®Google Scholar
• Gianoti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS. 2007;21:1648–1651.
   PubMed Web of Science ®Google Scholar
• Mahnke L, Child M, Satin L, et al. Electrocardiogram changes in HIV-infected, drug experienced patients treated with atazanavir. AIDS. 2008;22:1698.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Labeling changes for Kale-tra reflecting new QT/QTC interval and PR interval pro-longation information 4/6/2009. Available at: http://www.fda.gov/oashi/aids/listserve/listserve2009.html#4709. Accessed May 8, 2009.
   Google Scholar
• Hentig N, Kaykhin P, Stephan C, et al. Decrease of ata-zanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhib-itor salvage regimen. Antimicrob Agents Chemother. 2008;52:2273–2275.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Updated labeling for Nor-vir (ritonavir) soft capsule and oral solution. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed September 5,2008.
   Google Scholar
• Rossi DR, Rathbun RC, Slater LN. Symptomatic ortho-stasis with extended-release nifedipine and HIV protease inhibitors. Pharmacotherapy. 2002;22:1312–1316.
   PubMed Web of Science ®Google Scholar
• Anson BD, Weaver JGR, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682–686.
   PubMed Web of Science ®Google Scholar